Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain

Phase 4CompletedNCT01902524

Janssen Korea, Ltd., Korea65 enrolled

Overview

The purpose of this study is to confirm effectiveness and safety of fentanyl transdermal patch Durogesic® D-Trans for treatment of chronic pain in participants with chronic non-cancer pain.

This trial is a Phase 4, prospective, open-label (meaning that both the research physician and study participants will know which medication is being administered) study of fentanyl transdermal patch-type system (TTS) Durogesic® D-Trans in patients with non-cancer pain. The patch is designed to systematically release the adsorbed fentanyl percutaneously, in a constant rate for three days (72 hours). The study will be conducted for 12 weeks. The efficacy and safety will be evaluated at week 1, week 4, week 8 and week 12 visits. All participants will use the patch at least once during the study. The drug efficacy will be evaluated by the percent change in pain intensity before and after treatment and by improvements in the following activities: daily life, walking, meal intake, mood regulation. The overall safety will be assessed based on the adverse events reporting.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Pain

Interventions

Fentanyl-TTSDRUG

All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * spine related and extremity pain lasting for 3 months or longer * pain with Numeric Rating Scale (NRS) at 4 or higher in the past 72 hours * good overall health condition based on the medical history and clinical laboratory tests * participants using appropriate contraception in case of childbearing potential during the study period. Exclusion Criteria: * history of hypersensitive reaction to narcotic analgesics * history of narcotic abuse * serious psychotic disorder * unable to use transdermal analgesics due to a dermatological condition * history of CO2 retention (e.g., chronic obstructive pulmonary disease) * surgery in the area with pain within 7 days prior to initiation of the clinical study.

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

The change in pain intensity

The percent change in Pain Intensity Difference (PID) after study treatment (Week 12) compared to Day 0, prior to study treatment.

Time frame: Baseline, 12 weeks

Secondary Outcomes

Daily dose of prescribed medication

Change in daily dose of study medication prescribed at Day 0 and after 1, 4, 8 weeks.

Time frame: 12 weeks

Change in functionality

Satisfaction in functionality by participants evaluated at day 0 and after 1, 4, 8 and 12 weeks of treatment, measured as improvements in change of scores from 0 (not disturbing) to 10 (completely disturbing).

Time frame: 12 weeks

Change in sleep

Change in the frequency of waking up due to pain during the sleep.

Time frame: 12 weeks

Satisfaction in study medication

Satisfaction in study medication by participants and investigators summarized at Week 4, 8 and 12 visits.

Time frame: 12 weeks

The number of participants reporting adverse events (AEs)

All AEs during the study period will be reported.

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.